Achim A. Jungbluth
#161,392
Most Influential Person Now
Achim A. Jungbluth's AcademicInfluence.com Rankings
Achim A. Jungbluthbiology Degrees
Biology
#12808
World Rank
#16309
Historical Rank
Immunology
#862
World Rank
#885
Historical Rank
Neuroscience
#2175
World Rank
#2236
Historical Rank
Download Badge
Biology
Why Is Achim A. Jungbluth Influential?
(Suggest an Edit or Addition)Achim A. Jungbluth's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (2005) (2181)
- Immunologic correlates of the abscopal effect in a patient with melanoma. (2012) (1745)
- Cancer/testis antigens, gametogenesis and cancer (2005) (1495)
- Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. (2008) (893)
- Cancer/testis antigens: an expanding family of targets for cancer immunotherapy (2002) (865)
- Characterization of tumor necrosis factor-deficient mice. (1997) (841)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (2018) (816)
- CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma (2007) (464)
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. (2004) (460)
- Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. (2000) (420)
- Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues (2001) (351)
- Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. (2007) (350)
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma. (2018) (340)
- CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens (2008) (338)
- NY-ESO-1: review of an immunogenic tumor antigen. (2006) (336)
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit (2008) (335)
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011) (323)
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming (2007) (312)
- Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions (2017) (301)
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls (2019) (296)
- NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. (2003) (243)
- Merkel Cell Polyomavirus Expression in Merkel Cell Carcinomas and Its Absence in Combined Tumors and Pulmonary Neuroendocrine Carcinomas (2009) (238)
- Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients (2012) (237)
- Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 (2008) (237)
- L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition (2007) (233)
- Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement (2015) (220)
- Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage (2006) (217)
- Expression of MAGE‐antigens in normal tissues and cancer (2000) (216)
- Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. (1996) (216)
- A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. (1998) (215)
- Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. (2001) (214)
- Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. (1998) (207)
- A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors (2007) (206)
- Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. (1998) (204)
- The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. (2005) (196)
- Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST (2016) (192)
- Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues (2009) (191)
- Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. (2002) (185)
- Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 (2001) (183)
- Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 (2004) (183)
- Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. (2002) (172)
- A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor (2003) (172)
- Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. (2007) (164)
- PRAME Expression in Melanocytic Tumors (2018) (156)
- Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. (2003) (151)
- A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma (2013) (150)
- BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities (2016) (148)
- NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma (2018) (147)
- Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. (1996) (143)
- Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours (2000) (143)
- Identification of cancer/testis genes by database mining and mRNA expression analysis (2002) (142)
- Melan-A, a new melanocytic differentiation marker. (1999) (141)
- Analysis of Microphthalmia Transcription Factor Expression in Normal Tissues and Tumors, and Comparison of Its Expression With S-100 Protein, gp100, and Tyrosinase in Desmoplastic Malignant Melanoma (2001) (138)
- Novel monoclonal antibody specific for the de2‐7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene (2002) (137)
- Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. (2000) (133)
- Inhibition of interferon γ induced interleukin 12 production: A potential mechanism for the anti-inflammatory activities of tumor necrosis factor (1998) (131)
- SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas (2019) (125)
- Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. (2001) (125)
- Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets (2016) (125)
- Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* (2004) (124)
- Human Papillomavirus 16-Associated Cervical Intraepithelial Neoplasia in Humans Excludes CD8 T Cells from Dysplastic Epithelium (2010) (122)
- T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. (2007) (122)
- Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma (2013) (121)
- Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. (2007) (119)
- The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies* (2000) (118)
- T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. (2011) (117)
- Immunomic analysis of human sarcoma (2003) (115)
- Visceral Leishmaniasis in Mice Devoid of Tumor Necrosis Factor and Response to Treatment (2000) (114)
- ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity (2017) (111)
- Expression of Melanocytic Differentiation Markers in Malignant Melanomas of the Oral and Sinonasal Mucosa (2001) (107)
- NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma (2012) (105)
- Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation. (1998) (105)
- BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology (2017) (104)
- Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478 (2003) (101)
- CT-X antigen expression in human breast cancer (2009) (101)
- Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity (2005) (101)
- Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions (2013) (100)
- Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes (2008) (99)
- Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase (2012) (99)
- Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization. (2020) (98)
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (97)
- Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma (2005) (95)
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade (2018) (94)
- Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission (2008) (92)
- Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. (2004) (91)
- NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors (2004) (90)
- Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications (2002) (90)
- Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase (2011) (90)
- CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases (2011) (89)
- Cancer-testis antigen expression in triple-negative breast cancer. (2011) (89)
- Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. (2008) (88)
- MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin (2011) (87)
- Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma (2006) (86)
- Phase I study of anticolon cancer humanized antibody A33. (2003) (86)
- A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low‐grade fibromyxoid sarcoma: A pathologic and molecular study of 18 cases (2015) (85)
- Expression of Melanocyte Differentiation Antigens and Ki-67 in Nodal Nevi and Comparison of Ki-67 Expression With Metastatic Melanoma (2002) (84)
- PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels (2001) (84)
- 124I-huA33 Antibody PET of Colorectal Cancer (2011) (83)
- PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. (2007) (83)
- Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes (2013) (82)
- IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. (2016) (81)
- Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type (2016) (80)
- Immunohistochemical Analysis of Novel Monoclonal Antibody PNL2 and Comparison With Other Melanocyte Differentiation Markers (2005) (78)
- Histologic Distinction Between Subungual Lentigo and Melanoma (2008) (77)
- Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial (2018) (76)
- Insights into pathogenesis of fatal COVID‐19 pneumonia from histopathology with immunohistochemical and viral RNA studies (2020) (75)
- Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (75)
- Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
- Expression of cancer-testis (CT) antigens in placenta. (2007) (73)
- CT7 (MAGE‐C1) antigen expression in normal and neoplastic tissues (2002) (73)
- Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma (2015) (72)
- Phase II study of extended-dose temozolomide in patients with melanoma. (2008) (70)
- Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1 (2004) (70)
- PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma (2018) (69)
- T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. (2000) (69)
- NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer (2004) (68)
- Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016) (66)
- Frequent expression of the novel cancer testis antigen MAGE‐C2/CT‐10 in hepatocellular carcinoma (2009) (65)
- Effect of TNF gene depletion on liver regeneration after partial hepatectomy in mice. (2001) (62)
- Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein (2013) (62)
- Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma (2015) (61)
- WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. (2013) (60)
- Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations (2019) (60)
- Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. (2005) (59)
- Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. (1998) (57)
- Cancer-testis (CT) antigen expression in medulloblastoma. (2008) (57)
- DNA methylation-based classification of sinonasal undifferentiated carcinoma (2019) (55)
- Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). (2006) (55)
- Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial (2013) (55)
- Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck (2004) (54)
- PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with PLAG1 genetic abnormalities (2018) (54)
- Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors (2020) (54)
- Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma (2019) (54)
- MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer (2011) (54)
- Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors (2011) (54)
- Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF (2008) (53)
- 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET (2011) (53)
- Cancer/testis (CT) antigens are expressed in fetal ovary. (2007) (51)
- NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy (2007) (50)
- V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma (2019) (50)
- The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study (2015) (49)
- Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications (2013) (48)
- Immunoreactivity with the Anti-MAGE Antibody 57B in Malignant Melanoma: Frequency of Expression and Correlation with Prognostic Parameters (2000) (48)
- Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. (2010) (48)
- A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes (2008) (48)
- Analysis of peripheral and local anti‐tumor immune response in esophageal cancer patients after NY‐ESO‐1 protein vaccination (2008) (48)
- Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. (2007) (48)
- Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250 (2011) (47)
- NY-ESO-1 antibody as a novel tumour marker of gastric cancer (2013) (46)
- Xanthogranulomas with inconspicuous foam cells and giant cells mimicking malignant melanoma: a clinical, histologic, and immunohistochemical study of three cases. (2000) (45)
- Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas (1999) (45)
- Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. (2003) (45)
- Trypanosoma cruzi as an effective cancer antigen delivery vector (2011) (45)
- JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management (2019) (44)
- Isoforms of the human PDZ-73 protein exhibit differential tissue expression. (1999) (43)
- Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. (2006) (43)
- Melanoma or not? Cancer testis antigens may help (2004) (42)
- Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases (2006) (42)
- Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors (2019) (42)
- Diffuse melanosis after chemotherapy‐induced tumor lysis syndrome in a patient with metastatic melanoma (2004) (41)
- Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing (2020) (40)
- Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6–NTRK3 fusion (2020) (40)
- Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. (2004) (40)
- Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing (2014) (39)
- OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. (2006) (39)
- High expression of cancer testis antigens MAGE‐A, MAGE‐C1/CT7, MAGE‐C2/CT10, NY‐ESO‐1, and gage in advanced squamous cell carcinoma of the larynx (2011) (37)
- Primary Renal Sclerosing Epithelioid Fibrosarcoma: Report of 2 Cases With EWSR1-CREB3L1 Gene Fusion (2015) (37)
- NY-BR-1 is a Differentiation Antigen of the Mammary Gland (2007) (36)
- Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence (2008) (36)
- YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics (2018) (35)
- Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens (2003) (35)
- Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination (2012) (35)
- Expression of cancer–testis antigens in endometrial carcinomas using a tissue microarray (2005) (35)
- The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinoma (2019) (34)
- Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? (2011) (34)
- Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels (2007) (33)
- Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells (2012) (33)
- Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. (2004) (33)
- Spitz Tumors (2016) (33)
- Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. (2000) (32)
- Targeted drug distribution in tumor extracellular fluid of GD2‐expressing neuroblastoma patient‐derived xenografts using SN‐38‐loaded nanoparticles conjugated to the monoclonal antibody 3F8 (2017) (32)
- PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. (2001) (32)
- Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates (2016) (31)
- Inter‐ and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma (2020) (31)
- The differentiation antigen NY‐BR‐1 is a potential target for antibody‐based therapies in breast cancer (2007) (30)
- Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. (2009) (30)
- Expression and immunogenicity of NY‐ESO‐1 in hepatocellular carcinoma (2006) (30)
- Reduced H3K27me3 Expression in Merkel Cell Polyoma Virus-Positive Tumors (2017) (29)
- Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors (2011) (29)
- Neuropilin-2: a novel biomarker for malignant melanoma? (2012) (29)
- SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. (2004) (29)
- Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. (2006) (29)
- SSX antigens as tumor vaccine targets in human sarcoma. (2003) (28)
- Jungbluth AA, Chen Y‐T, Stockert E., Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues. International Journal of Cancer 2001; 92(6) 856–860. (2002) (28)
- Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy (2003) (28)
- A Performance Comparison of Commonly Used Assays to Detect RET Fusions (2020) (28)
- A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacokinetics, immunohistochemistry, and quantitative tumor uptake. (2004) (27)
- TFEB Expression Profiling in Renal Cell Carcinomas (2019) (27)
- The recombinant catalytic domain of mouse collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides. (1997) (27)
- Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma (2018) (26)
- Anatomic position determines oncogenic specificity in melanoma (2020) (25)
- HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma (2016) (24)
- Immunohistochemical and Reverse Transcription-Polymerase Chain Reaction Expression Analysis of Tyrosinase and Microphthalmia-Associated Transcription Factor in Angiomyolipomas (2001) (23)
- A phase I clinical trial with monoclonal antibody ch 806 targeting transitional state and mutant epidermal growth factor receptors (2007) (23)
- Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi. (2000) (23)
- Pharmacokinetics and microdistribution of polyethylene glycol‐modified humanized A33 antibody targeting colon cancer xenografts (2000) (23)
- MAGE antigen expression in monophasic and biphasic synovial sarcoma. (2002) (23)
- Expression of cancer testis (CT) antigens in ovary (2004) (22)
- Clusterin expression in primary and metastatic melanoma (2006) (22)
- Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules (2017) (22)
- Expression of cancer‐testis antigens MAGE‐A4 and MAGE‐C1 in oral squamous cell carcinoma (2012) (22)
- Immunohistochemical Analysis of IDH2 R172 Hotspot Mutations in Breast Papillary Neoplasms: Applications in the Diagnosis of Tall Cell Carcinoma with Reverse Polarity (2019) (22)
- SCLC Subtypes De fi ned by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization (2020) (22)
- Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (22)
- Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation (2020) (21)
- A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma (2006) (20)
- T‐cell receptor‐δ expression and γδ+ T‐cell infiltrates in primary cutaneous γδ T‐cell lymphoma and other cutaneous T‐cell lymphoproliferative disorders (2018) (20)
- Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (20)
- Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues (2020) (20)
- Expression of MAGE antigens and analysis of the inflammatory T-cell infiltrate in human seminoma (2000) (20)
- Immunohistochemical Detection of γ/δ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues (2019) (20)
- Histone H3K36M mutation and trimethylation patterns in chondroblastoma (2018) (19)
- A Molecular Reappraisal of Glomus Tumors and Related Pericytic Neoplasms With Emphasis on NOTCH-gene Fusions (2020) (19)
- Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma (2012) (18)
- The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma (2018) (17)
- Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients (2012) (17)
- Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas (2019) (16)
- CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki‐67 clone 30‐9 is not susceptible to the inhibition: Critical diagnostic implications (2019) (16)
- Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. (2011) (16)
- Monoclonal antibody MX 35 detects the membrane transporter NaPi 2 b ( SLC 34 A 2 ) in human carcinomas (2005) (15)
- Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. (2019) (15)
- IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies (2021) (15)
- THE NEW MELANOMA MARKERS : MART-1 AND MELAN-A (THE NIH EXPERIENCE) (1999) (14)
- Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. (2013) (14)
- Monitoring CD 8 T cell responses to NY-ESO-1 : correlation of humoral and cellular immune responses (2017) (13)
- Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. (2005) (13)
- Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma (2015) (13)
- Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma (2020) (13)
- Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms (2017) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors (2019) (13)
- Inhibition of interferon g induced interleukin 12 production : A potential mechanism for the anti-inflammatory activities of tumor necrosis factor (1998) (13)
- An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients (2011) (12)
- TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition (2021) (12)
- PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions. (2021) (11)
- Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor (2020) (11)
- Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors. (2014) (11)
- Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using 18F-FLT PET (2013) (11)
- A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled By Clinical Genomic Sequencing. (2020) (11)
- Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer. (2019) (10)
- POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. (2022) (10)
- Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes (2020) (10)
- Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma (2019) (10)
- Protein S100 as Prognostic Marker for Gastrointestinal Stromal Tumors: A Clinicopathological Risk Factor Analysis (2007) (10)
- Molecular Epidemiology of IDH2 Hotspot Mutations in Cancer and Immunohistochemical Detection of R172K, R172G and R172M Variants. (2020) (9)
- A Novel Technique for the Generation of Multitissue Blocks Using a Carrier (2016) (8)
- Proteomic analysis shows that the main constituent of subepidermal localised cutaneous amyloidosis is not galectin-7 (2020) (8)
- Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). (2010) (8)
- Cancer-testis antigen expression and immunogenicity in AL amyloidosis (2012) (8)
- Genomic characterization of small cell carcinomas of the uterine cervix (2021) (7)
- B- Cell Maturation Antigen Is Exclusively Expressed in a Wide Range of B-Cell and Plasma Cell Neoplasm and in a Potential Therapeutic Target for Bcma Directed Therapies (2017) (7)
- RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. (2016) (7)
- Serological reagents for the immunohistochemical analysis of melanoma metastases in sentinel lymph nodes. (2008) (7)
- Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder (2019) (7)
- Immunohistochemical Detection of Cancer-Testis Antigen PRAME (2021) (7)
- MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT) (2013) (7)
- Cancer–Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma (2014) (6)
- Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases (2017) (6)
- YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. (2017) (6)
- A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract (2020) (6)
- Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy (2019) (6)
- Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). (2016) (6)
- Immunohistochemistry for the Diagnosis of Melanocytic Proliferations (2019) (6)
- Expression of mage‐A4 and mage‐C1 tumor‐associated antigen in benign and malignant thyroid diseases (2011) (5)
- Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2 (2016) (4)
- Targeting Lewis Y (LeY) in small cell lung cancer (SCLC) with a humanized monoclonal antibody, hu3S193. (2006) (4)
- Target discovery for T cell therapy: next steps to advance Immunotherapies (2015) (4)
- Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patients (2022) (4)
- Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM) (2014) (4)
- Chromosome 3p loss of heterozygosity and reduced H3K36me3 correlate with longer relapse free survival in sacral conventional chordoma. (2020) (4)
- Generation of monoclonal antibodies to cancer / testis ( CT ) antigen CT 10 / MAGE-C 2 (2005) (4)
- Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702)) (2005) (4)
- Initial steps of the metal-catalysed degradation of L-dehydroascorbic acid in acidic aqueous solutions (1997) (4)
- Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis (2018) (3)
- Cancer-testis (CT) antigen expression in (2008) (3)
- Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer. (2012) (3)
- A phase 1 clinical trial of NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM® adjuvant) in patients with minimal residual disease (2003) (3)
- Long-term remission after CD34+-selected PBSCT in a patient with advanced intra-abdominal desmoplastic small round-cell tumor (2010) (3)
- Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis (2021) (3)
- WT1-Specific Immune Responses in Patients with High-Risk Multiple Myeloma Undergoing Allogeneic T Cell-Depleted Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions (2011) (3)
- MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells (2010) (3)
- Loss of PD-L1 Immunoexpression in CytoLyt-Fixed Cell Blocks (2017) (3)
- PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays (2021) (2)
- [Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas]. (2017) (2)
- Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma. (2014) (2)
- Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma (2017) (2)
- Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses (2005) (2)
- Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma (2015) (2)
- Th 1 / Th 2 CD 4 + T cell responses against NY-ESO-1 in HLA-DPB 1 * 0401 / 0402 patients with epithelial ovarian cancer (2004) (2)
- Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches (2015) (2)
- Multilineage plasticity in prostate cancer through expansion of stem–like luminal epithelial cells with elevated inflammatory signaling (2021) (2)
- Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma (2013) (2)
- A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence (2013) (2)
- CD8+ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients. (2006) (2)
- mTOR Pathway Activation Assessed by Immunohistochemistry in Cervical Biopsies of HPV-associated Endocervical Adenocarcinomas (HPVA): Correlation With Silva Invasion Patterns (2021) (2)
- Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (2012) (2)
- Expression von Cancer-Testis(CT)-Antigenen in Melanomen des Kindes- und Jugendalters (2017) (2)
- Benign Breast Tumors NY-ESO-1 Expression and Immunogenicity in Malignant and Updated (2004) (1)
- Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease. (2006) (1)
- Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications (2013) (1)
- Expression Analysis of GD2 by Immunohistochemistry in Invasive Breast Carcinoma: Clinical and Pathologic Correlation. (2021) (1)
- CT7 (MAGE-C1) is a widely expressed Cancer-Testis antigen in multiple myeloma. (2004) (1)
- YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs). (2020) (1)
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 (cid:1) and CD8 (cid:1) T cell responses in humans (2004) (1)
- Cervical mucosal CD8 T cells are more predictive of HPV lesion regression than systemic HPV-specific response (48.13) (2010) (1)
- Advances in Brief NY-ESO-1 Expression and Immunogenicity Associated with Transitional Cell Carcinoma : Correlation with Tumor Grade 1 (2001) (1)
- VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy? (2022) (1)
- WT1-Specific T-Cell Responses Following T Cell-Depleted Allogeneic Hematopoietic Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients with High-Risk Multiple Myeloma (2012) (1)
- YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics (2018) (1)
- Targeting Wilms' Tumor 1 Protein Following CD34-Selected Allografts By Adoptive Transfer of Donor-Derived CTLs in Patients with Advanced Multiple Myeloma (2016) (1)
- A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission. (2010) (1)
- JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation (2018) (1)
- Abstract 4519: Small cell lung cancers lack expression of argininosuccinate synthase (ASS) and are sensitive to arginine deprivation using arginine deiminase-PEG20 (ADI-PEG20) (2010) (1)
- Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma (2016) (1)
- MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival (2008) (1)
- Wilms’ tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches (2015) (1)
- CT7 mRNA and protein are widely expressed in multiple myeloma (2003) (0)
- Immunophenotype of regionally recurrent melanoma of the extremity in patients before isolated limb infusion (ILI). (2006) (0)
- SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors (2022) (0)
- PP29 Tissue factor expression in colorectal cancer: a surrogate for KRAS and p53? (2009) (0)
- Gene expression profile pregnancy reveals similar genetic program in cancer and placenta development: identification of novel targets for cancer immunotherapy (2010) (0)
- OP055: High expressipon of cancer/testis antigens in oral squamous cell carcinoma (2013) (0)
- Distinctive Expression of Cancer/Testis-X Antigens in a Subset of ER Negative Breast Carcinomas. (2009) (0)
- Uptake of 124I-huA33 in colorectal tumors in patients assessed by post-surgical digital autoradiography (2008) (0)
- induce systemic immunity following allogeneic stem cell transplantation Cancer-testis antigens are commonly expressed in multiple myeloma and (2013) (0)
- Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity [superscript 86]Y- or [superscipt 177]Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates (2015) (0)
- Type I MAGE Proteins: Novel Markers of Proliferation in Multiple Myeloma Progenitor Cells. (2005) (0)
- Expression of cancer testis (CT) antigens in human BRCA-associated breast cancers: Potential targets for immunoprevention? (2011) (0)
- Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (0)
- Expression of Cancer Testis Antigens (CTAs) in Plasmacytoma with and without Bone Marrow Involvement (2015) (0)
- 234 Clonality analysis of synchronous endometrial and ovarian carcinomas in patients with lynch syndrome (2019) (0)
- MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma. (2009) (0)
- T1915 Anti-Lewis Y Antibody As a Novel Target for Pancreatic Adenocarcinoma (2008) (0)
- CT7/MAGE-C1 Expression and Immune Responses Following Allogeneic Transplant for Multiple Myeloma (2013) (0)
- Immunophenotyping of human tumor antigens (2003) (0)
- Adjuvant Using TLR 7 Agonist Imiquimod as Vaccine Patients with Full-Length NY-ESO-1 Protein Immunization of Malignant Melanoma (2008) (0)
- QS320. Anti-Lewis Y Antibody As a Novel Target for Gastric Adenocarcinoma (2008) (0)
- Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (0)
- Su.98. Mechanisms of Immune Privilege in High Grade Cervical Dysplasia (2008) (0)
- Abstract 3379: Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven byHRAShotspot mutations (2017) (0)
- Phase I safety and immunogenicity study of NY-ESO-1b peptide and Montanide ISA-51 vaccination of patients with ovarian cancer (OC) in high risk first remission. (2006) (0)
- Abstract LB-116: Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution (2015) (0)
- Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (0)
- Cancer testis antigen (PRAME) as an independent marker for survival in Oral Squamous Cell Carcinoma (OSCC). (2022) (0)
- Retrovirus GAG Protein Humoral Immune Response to a Human Endogenous Prostate Cancer Progression Correlates with Increased (2013) (0)
- A103 andT311: two new monoclonal antibodies against the Melan-A (MART-1) and tyrosinase antigens for use on formalin-fixed paraffin-embedded tissues (1997) (0)
- Expression of Cancer Testis (CT) Antigens NY-ESO-1 and LAGE-1 in Multiple Myeloma (MM): Could a Vaccine against the Former Antigen Be Effective against the Latter? (2009) (0)
- Cancer Testis Antigens and Immunotherapy: Expression of PRAME and NY-ESO-1 Predicts Survival in Soft Tissue Sarcoma (2020) (0)
- Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. (2022) (0)
- Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma. (2015) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Lineage plasticity is a well–established mechanism of resistance to targeted therapies in lung and prostate cancer, where tumors transition from adenocarcinoma to small–cell or neuroendocrine carcinoma. Through single–cell analysis of a cohort of heavily–treated castration–resistant human prostate c (2021) (0)
- Cancer-Testis (CT) Antigen Expression In AL Amyloidosis (2010) (0)
- MAGE-3 Protein in Lung Cancer Patients Vaccine-Induced CD4+ T Cell Responses to (2013) (0)
- Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (0)
- Phase II trial of extended-dosing temozolomide in patients with melanoma. (2006) (0)
- Epilepsy in children with perinatal arterial ischemic stroke (2021) (0)
- Cancer Immunity (12 July 2007) Vol. 7, p. 11 (2005) (0)
- BCG-Induced Tumor Immunity Requires Tumor-Intrinsic CIITA Independent of MHC-II. (2022) (0)
- Cancer Immunity (12 January 2006) Vol. 6, p. 2 (2005) (0)
- Pilot study of MAGE-A3 protein vaccination and autologous stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM). (2012) (0)
- Vaccination and immunotherapy of viral diseases (WS-069) Chairpersons: Tetsuro Matano, Rene van Lier (2010) (0)
- Recombinant MAGE-A3 protein immunotherapy and peripheral blood lymphocyte (PBL) reconstitution induce strong antigen-specific humoral and cellular immune responses in patients undergoing autologous stem cell transplantation (ASCT) for consolidation of multiple myeloma (MM) (2015) (0)
- P2.06-40 VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression (2018) (0)
- Chimeric G250 in Metastatic Renal Cancer (2004) (0)
- A34 — Expression of a novel differentiation antigen of the stomach mucosa on a protein level (2004) (0)
- Hox genes and laryngeal carcinogenesis (2019) (0)
- Expression of Novel Neuroendocrine Markers in Breast Carcinomas A Study of INSM1, ASCL1 and POU2F3. (2022) (0)
- Expression of Cancer-Testis Antigens in Non-Hodgkin’s Lymphomas (2008) (0)
- Phase II trial of extended-dosing temozolomide in patients with melanoma (2006) (0)
- Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
- Abstract P3-10-40: Expression and Prognostic Significance of Cancer Testis Antigens (CTA) in Primary Breast Cancer: Possible Diagnostic Markers and Therapeutical Targets (2010) (0)
- Expression of melanocyte differentiation antigens Melan-A and tyrosinase in Clear Cell Sarcomas (2002) (0)
- transplantation and donor lymphocyte infusions depleted hematopoietic stem cell − undergoing allogeneic T cell WT 1-specific T-cell responses in high-risk multiple myeloma patients (2013) (0)
- MAGE-3 Protein in Lung Cancer Patients T Cell Responses to + Vaccine-Induced CD4 (2004) (0)
- Tumors by CD 4 Tumor Antigen for Direct Recognition of Peptide-Selective Presentation of Cytosolic Heat Shock Protein 90-Mediated Old and (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Achim A. Jungbluth?
Achim A. Jungbluth is affiliated with the following schools:
